Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Short Interest Update

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) was the target of a large growth in short interest in July. As of July 15th, there was short interest totaling 70,670 shares, a growth of 154.3% from the June 30th total of 27,790 shares. Based on an average daily volume of 30,445 shares, the days-to-cover ratio is currently 2.3 days. Currently, 2.3% of the company’s shares are sold short.

Insider Activity at Pelthos Therapeutics

In related news, Director Todd C. Davis purchased 35,948 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The stock was bought at an average cost of $27.82 per share, with a total value of $1,000,073.36. Following the completion of the purchase, the director directly owned 75,834 shares in the company, valued at approximately $2,109,701.88. This represents a 90.13% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last three months, insiders have sold 1,638 shares of company stock valued at $43,107. Company insiders own 12.70% of the company’s stock.

Hedge Funds Weigh In On Pelthos Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Ikarian Capital LLC boosted its holdings in shares of Pelthos Therapeutics by 309.5% in the 4th quarter. Ikarian Capital LLC now owns 255,758 shares of the company’s stock worth $7,928,000 after purchasing an additional 193,307 shares during the period. Boothbay Fund Management LLC boosted its stake in Pelthos Therapeutics by 279.8% during the fourth quarter. Boothbay Fund Management LLC now owns 80,680 shares of the company’s stock worth $2,501,000 after buying an additional 59,435 shares during the period. J. Goldman & Co LP bought a new position in Pelthos Therapeutics during the fourth quarter valued at $2,418,000. Cantor Fitzgerald L. P. purchased a new stake in shares of Pelthos Therapeutics in the fourth quarter valued at $1,085,000. Finally, Diadema Partners LP raised its stake in shares of Pelthos Therapeutics by 138.1% in the fourth quarter. Diadema Partners LP now owns 25,000 shares of the company’s stock valued at $775,000 after acquiring an additional 14,502 shares during the period. Hedge funds and other institutional investors own 77.96% of the company’s stock.

Pelthos Therapeutics Price Performance

Shares of NYSEAMERICAN:PTHS traded down $2.03 during midday trading on Wednesday, hitting $25.74. The company had a trading volume of 72,326 shares, compared to its average volume of 20,857. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.86 and a current ratio of 2.79. The firm has a market cap of $89.58 million, a P/E ratio of -1.25 and a beta of 3.10. Pelthos Therapeutics has a 12-month low of $16.50 and a 12-month high of $37.50. The business has a fifty day simple moving average of $27.09.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($3.09) earnings per share (EPS) for the quarter. The company had revenue of $10.91 million during the quarter. Research analysts expect that Pelthos Therapeutics will post -12.63 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on PTHS shares. Oppenheimer lifted their price objective on Pelthos Therapeutics from $62.00 to $66.00 and gave the stock an “outperform” rating in a report on Friday, May 15th. Cantor Fitzgerald initiated coverage on shares of Pelthos Therapeutics in a report on Wednesday, April 1st. They set an “overweight” rating and a $50.00 price target on the stock. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Pelthos Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $55.80.

Pelthos Therapeutics Company Profile

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).